Matches in SemOpenAlex for { <https://semopenalex.org/work/W2225873170> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2225873170 endingPage "601" @default.
- W2225873170 startingPage "601" @default.
- W2225873170 abstract "601 Purpose: The present study was aimed at defining the antitumor activity of 8 PET weekly cycles with G-CSF support in patients with large operable breast cancer. Methods: Breast cancer (T2-T3 N0–1) patients received 8 weekly cycles of cisplatin 30 mg/sqm, epirubicin 50 mg/sqm, paclitaxel 120 mg/sqm, with G-CSF (5 microgr./kg days 3–5) support. Results: To date 47 patients (T2/T3=19/28; N0/N+=8/39) have been enrolled. Forty patients have completed the planned chemotherapy plan, and are evaluable for clinical and pathological response. Twenty Complete (50%), 19 Partial (48%), and 1 Minor Responses have been recorded, giving a 98% response rate [95% confidence interval, 84–100%]. Breast-sparing surgery was performed in 24/40 patients (in 15 radical mastectomy had been planned at diagnosis). At pathological assessment, 20 patients (50%) showed absence of residual disease in breast and 19 (48%) had negative axilla. In 14 women both breast and axilla were found disease-free (35%). At a 33-month median follow-up (range; 1–45), only 4 relapses, and one death have occurred. Grade 3–4 neutropenia, and anemia occurred in 27% and 5% of patients, respectively. Emesis, diarrhea, and mucositis were the main non-hematologic toxicities; however, they were severe in less than 10% of patients. Peripheral neuropathy was frequent, but never severe. Conclusions: A Two-month weekly treatment with PET represents a well tolerated and highly effective approach in large operable breast cancer patients. It is worth-noting that in spite of the short duration of chemotherapy more than one-third of patients achieved a complete eradication of the tumor in both breast and axilla. The accrual is still ongoing (planned sample size being 50 patients), and we expect that final results will be available at the time of the meeting. No significant financial relationships to disclose." @default.
- W2225873170 created "2016-06-24" @default.
- W2225873170 creator A5000899494 @default.
- W2225873170 creator A5004747884 @default.
- W2225873170 creator A5005243891 @default.
- W2225873170 creator A5015849958 @default.
- W2225873170 creator A5029509828 @default.
- W2225873170 creator A5036070767 @default.
- W2225873170 creator A5036696158 @default.
- W2225873170 creator A5056559714 @default.
- W2225873170 creator A5073695437 @default.
- W2225873170 creator A5091889243 @default.
- W2225873170 date "2004-07-15" @default.
- W2225873170 modified "2023-09-27" @default.
- W2225873170 title "Two-month cisplatin-epirubicin-paclitaxel (PET) weekly administration for the treatment of large operable breast cancer. SICOG 0105 phase II study" @default.
- W2225873170 doi "https://doi.org/10.1200/jco.2004.22.14_suppl.601" @default.
- W2225873170 hasPublicationYear "2004" @default.
- W2225873170 type Work @default.
- W2225873170 sameAs 2225873170 @default.
- W2225873170 citedByCount "0" @default.
- W2225873170 crossrefType "journal-article" @default.
- W2225873170 hasAuthorship W2225873170A5000899494 @default.
- W2225873170 hasAuthorship W2225873170A5004747884 @default.
- W2225873170 hasAuthorship W2225873170A5005243891 @default.
- W2225873170 hasAuthorship W2225873170A5015849958 @default.
- W2225873170 hasAuthorship W2225873170A5029509828 @default.
- W2225873170 hasAuthorship W2225873170A5036070767 @default.
- W2225873170 hasAuthorship W2225873170A5036696158 @default.
- W2225873170 hasAuthorship W2225873170A5056559714 @default.
- W2225873170 hasAuthorship W2225873170A5073695437 @default.
- W2225873170 hasAuthorship W2225873170A5091889243 @default.
- W2225873170 hasConcept C121608353 @default.
- W2225873170 hasConcept C126322002 @default.
- W2225873170 hasConcept C141071460 @default.
- W2225873170 hasConcept C143998085 @default.
- W2225873170 hasConcept C2776694085 @default.
- W2225873170 hasConcept C2777063308 @default.
- W2225873170 hasConcept C2778496288 @default.
- W2225873170 hasConcept C2778850193 @default.
- W2225873170 hasConcept C2780835546 @default.
- W2225873170 hasConcept C530470458 @default.
- W2225873170 hasConcept C71924100 @default.
- W2225873170 hasConcept C90924648 @default.
- W2225873170 hasConceptScore W2225873170C121608353 @default.
- W2225873170 hasConceptScore W2225873170C126322002 @default.
- W2225873170 hasConceptScore W2225873170C141071460 @default.
- W2225873170 hasConceptScore W2225873170C143998085 @default.
- W2225873170 hasConceptScore W2225873170C2776694085 @default.
- W2225873170 hasConceptScore W2225873170C2777063308 @default.
- W2225873170 hasConceptScore W2225873170C2778496288 @default.
- W2225873170 hasConceptScore W2225873170C2778850193 @default.
- W2225873170 hasConceptScore W2225873170C2780835546 @default.
- W2225873170 hasConceptScore W2225873170C530470458 @default.
- W2225873170 hasConceptScore W2225873170C71924100 @default.
- W2225873170 hasConceptScore W2225873170C90924648 @default.
- W2225873170 hasIssue "14_suppl" @default.
- W2225873170 hasLocation W22258731701 @default.
- W2225873170 hasOpenAccess W2225873170 @default.
- W2225873170 hasPrimaryLocation W22258731701 @default.
- W2225873170 hasRelatedWork W1982206062 @default.
- W2225873170 hasRelatedWork W2102184759 @default.
- W2225873170 hasRelatedWork W2108932646 @default.
- W2225873170 hasRelatedWork W2122468945 @default.
- W2225873170 hasRelatedWork W2157622595 @default.
- W2225873170 hasRelatedWork W2418847095 @default.
- W2225873170 hasRelatedWork W262147024 @default.
- W2225873170 hasRelatedWork W2947501674 @default.
- W2225873170 hasRelatedWork W2989639282 @default.
- W2225873170 hasRelatedWork W2182222500 @default.
- W2225873170 hasVolume "22" @default.
- W2225873170 isParatext "false" @default.
- W2225873170 isRetracted "false" @default.
- W2225873170 magId "2225873170" @default.
- W2225873170 workType "article" @default.